Related Experiment Video
Updated: Jul 7, 2026

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
Published on: March 16, 2018
[Loop diuretics and ototoxicity]
R Martínez-Rodríguez1, J García Lorenzo, J Bellido Peti
1Servicio Urología Fundación Puigvert, Barcelona. hugomar2@yahoo.es
Loop diuretics like furosemide are common medications. While generally safe, they can cause rare, reversible hearing loss (ototoxicity), though permanent deafness has been documented.
Area of Science:
- Pharmacology
- Ototoxicology
Background:
- Loop diuretics, including furosemide, are widely utilized in clinical settings.
- Despite a generally favorable safety profile, potential adverse events necessitate awareness for early detection.
Observation:
- Ototoxicity, or hearing impairment, is an infrequent adverse event associated with furosemide.
- The ototoxicity linked to furosemide is typically reversible upon recognition and management.
Findings:
- While reversible hearing loss is more common, there are documented instances of permanent deafness resulting from furosemide administration.
- This highlights a rare but severe potential side effect of this commonly used drug.
Implications:
- Clinicians should be vigilant for signs of ototoxicity in patients receiving furosemide.
- Early recognition and intervention are crucial to mitigate the risk of permanent hearing damage.
- Understanding these risks is vital for patient safety and informed therapeutic decisions.
More Related Videos
12:21The Mouse Round-window Approach for Ototoxic Agent Delivery: A Rapid and Reliable Technique for Inducing Cochlear Cell Degeneration
Published on: November 26, 2015
09:18A Comparative Study of Drug Delivery Methods Targeted to the Mouse Inner Ear: Bullostomy Versus Transtympanic Injection
Published on: March 8, 2017
Related Concept Videos
Heart Failure Drugs: Diuretics
Antihypertensive Drugs: Potassium-Sparing Diuretics
Antihypertensive Drugs: Action of Diuretics
Antihypertensive Drugs: Thiazide-Class Diuretics
Physiology of the Genitourinary System II: Tubular Reabsorption and Secretion
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions